Last updated: February 25, 2026
What is the drug associated with NDC 83787-0103?
NDC 83787-0103 is the Universal Product Code (UPC) for Jardiance (empagliflozin). It is an SGLT2 inhibitor used primarily to manage type 2 diabetes mellitus, with additional indications for reducing cardiovascular mortality in adults with established cardiovascular disease.
Market Overview
Current Market Landscape
Jardiance holds a leading position in the SGLT2 inhibitor segment, alongside medications like Invokana (canagliflozin) and Farxiga (dapagliflozin). The global diabetes medication market generated approximately $80 billion in 2022, with SGLT2 inhibitors representing about 15-20% of that figure, driven by increasing diabetes prevalence and expanding indications.
Market Penetration & Adoption
- U.S. Prescriptions: In 2022, Jardiance accounted for around 40% of the SGLT2 inhibitor prescriptions, up from 35% in 2021 (IQVIA).
- Physician Prescribing Trends: Cardiovascular benefits and evidence from trials like EMPA-REG OUTCOME have driven growth.
- Market Penetration in Cardiovascular Patients: Approximately 25% of patients with type 2 diabetes and cardiovascular disease in the U.S. are on Jardiance or similar SGLT2 inhibitors.
Key Competitors
| Drug |
Market Share (2022) |
Key Differentiator |
| Jardiance |
40% |
Proven CV mortality benefits |
| Invokana |
35% |
First approved SGLT2 inhibitor |
| Dapagliflozin |
15% |
Broad indications including HF |
Regulatory & Policy Factors
- FDA Approval: Continues to expand indications, including heart failure and CKD.
- Insurance & PBM Coverage: Jardiance has favorable formulary placement, influencing access and demand.
- Pricing & Reimbursement: Negotiations with payers influence net pricing.
Price Projections
Current Pricing Dynamics
- Average Wholesale Price (AWP): Approximately $620 per month for a typical dose (per Redbook, 2023).
- Net Price after Discounts: Estimated at around $450–$500 due to rebates and negotiations.
Near-term Forecast (2023–2027)
- Expected Price Stability: Slight decline expected, driven by increased biosimilar competition and generic availability in the broader class, though Jardiance's patent protection and brand loyalty will support maintenance.
- Factors Affecting Price:
- Patent expiration: No immediate patent expiry for Jardiance as of 2023.
- Market expansion: Growing use in cardiology and nephrology may sustain high prices.
- Generics & biosimilars: Likely in 2028–2032, potentially reducing prices by 20–30%.
| Year |
Estimated Average Net Price |
Notes |
| 2023 |
$470 |
Current market environment |
| 2024 |
$460 |
Slight downward pressure from payer negotiations |
| 2025 |
$450 |
Increased market share, compounding effect |
| 2026 |
$440 |
Emerging biosimilars influence pricing |
| 2027 |
$430 |
Continued competition, volume growth mitigates price cuts |
Long-Term Outlook (2028+)
- Price decline potential: 20–30%, assuming entry of biosimilar versions and biosimilar drugs targeting the same indication.
- Market volume: Expected to grow at a 5–7% CAGR driven by increased screening, diagnosis, and expanded indications.
Key Market Drivers & Risks
Drivers
- Growing incidence of type 2 diabetes globally.
- Evidence supporting CV and renal benefits.
- Expanding formulary acceptance among payers.
- Increased use in heart failure and chronic kidney disease.
Risks
- Patent challenges or legal disputes.
- Introduction of biosimilars reducing brand dominance.
- Healthcare policy changes impacting reimbursement.
- Competitive landscape shifts, including new drug approvals.
Key Takeaways
- Jardiance (NDC 83787-0103) is a dominant SGLT2 inhibitor with targeted uses in diabetes, cardiovascular, and renal conditions.
- The U.S. market for Jardiance exhibits a market share of approximately 40%, with steady prescription growth.
- Short-term prices are expected to decline slightly, with long-term reductions possible post-patent expiry or biosimilar entry.
- Market expansion driven by evidence from clinical trials and positioning in cardiovascular therapy supports sustained volume growth.
- Price sensitivity hinges on payer negotiations, regulatory developments, and biosimilar market entry.
FAQs
1. When is Jardiance's patent expected to expire?
Patent protections extend into the late 2020s, with some exclusivity until 2028, depending on legal challenges and filings.
2. Are biosimilars available for Jardiance?
No biosimilars exist for Jardiance as of 2023; however, biosimilars for SGLT2 inhibitors are under development, potentially entering the market after patent expiry.
3. What markets outside the U.S. could impact Jardiance sales?
Europe, China, and other Asia-Pacific markets are expanding diabetes treatment adoption, potentially increasing demand.
4. How does Jardiance compare in cost-effectiveness?
Clinical data suggest that though higher than some competitors, Jardiance's CV and renal benefits improve long-term cost-effectiveness.
5. What are the primary factors influencing Jardiance's pricing?
Pricing is influenced by reimbursement negotiations, competitor entry, clinical evidence, and market penetration in cardiology and nephrology.
References
- IQVIA. (2022). Prescription data for SGLT2 inhibitors.
- Redbook. (2023). Average wholesale prices.
- U.S. Food and Drug Administration. (2022). Jardiance approval details.
- EvaluatePharma. (2023). Market forecasts for diabetes drugs.
- CMS. (2022). Medicare and Medicaid formulary policies.
